JP drafts for public comments, September 2 - 30, 2019
New General Test
- 2.05 Size Exclusion Chromatography (001-1909-1eng.pdf)
JP drafts for public comments, September 2 - November 30, 2019
Revised General Test
- 2.66 Elemental Impurities (002-1909-1eng.pdf)
Briefing on Proposed Revision
General Test "2.66 Elemental Impurities Procedures"New monographs
- Bicalutamide (003-1909-1eng.pdf)
- Celecoxib (004-1909-1eng.pdf)
- Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution (005-1909-1eng.pdf)
- Ethyl Loflazepate (006-1909-1eng.pdf)
- Ethyl Loflazepate Tablets (007-1909-1eng.pdf)
- Fenofibrate (008-1909-1eng.pdf)
- Fenofibrate Tablets (009-1909-1eng.pdf)
- Gefitinib (010-1909-1eng.pdf)
- Glucagon (Genetical Recombination) (011-1909-1eng.pdf)
- Heparin Sodium Lock Solution (012-1909-1eng.pdf)
- Heparin Sodium Solution for Dialysis (013-1909-1eng.pdf)
- Irinotecan Hydrochloride Injection (014-1909-1eng.pdf)
- Methotrexate for Injection (015-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate (016-1909-1eng.pdf)
- Rilmazafone Hydrochloride Tablets (017-1909-1eng.pdf)
- Rosuvastatin Calcium (018-1909-1eng.pdf)
- Rosuvastatin Calcium Tablets (019-1909-1eng.pdf)
- Zopiclone (020-1909-1eng.pdf)
- Zopiclone Tablets (021-1909-1eng.pdf)
Ultraviolet-visible reference spectra
- Bicalutamide (022-1909-1eng.pdf)
- Celecoxib (023-1909-1eng.pdf)
- Ethyl Loflazepate (024-1909-1eng.pdf)
- Fenofibrate (025-1909-1eng.pdf)
- Gefitinib (026-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate (027-1909-1eng.pdf)
- Rosuvastatin Calcium (028-1909-1eng.pdf)
- Zopiclone (029-1909-1eng.pdf)
Infrared reference spectra
- Bicalutamide (030-1909-1eng.pdf)
- Celecoxib (031-1909-1eng.pdf)
- Ethyl Loflazepate (032-1909-1eng.pdf)
- Fenofibrate (033-1909-1eng.pdf)
- Gefitinib (034-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate (035-1909-1eng.pdf)
- Rosuvastatin Calcium (036-1909-1eng.pdf)
- Zopiclone (037-1909-1eng.pdf)
To send the comment on these drafts, the guidance is as follows:
- Download the form for comments in Word format
- Fill in the form
- Prepare and attach the supportive data that scientifically validate the comment when appropriate
- Send it to the email address: JPdraft1909-1eng●pmda.go.jp
Note: For the purpose of security, this email address is partly incorrect. Please replace ● with @ when sending an email.
Related Information
Note: The information provided with the comment may be released to the public whenever necessary (except the individual name, organization, address, telephone & fax numbers and e-mail address or the attached supportive data).